Callan Capital buys $25.1 Million stake in Nantkwest Inc (NK)

Nantkwest Inc (NK) : Callan Capital scooped up 38,573 additional shares in Nantkwest Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 3,763,086 shares of Nantkwest Inc which is valued at $25.1 Million.Nantkwest Inc makes up approximately 10.82% of Callan Capital’s portfolio.

Other Hedge Funds, Including , Rs Investment Management Co boosted its stake in NK in the latest quarter, The investment management firm added 81,097 additional shares and now holds a total of 1,113,237 shares of Nantkwest Inc which is valued at $7.4 Million. Nantkwest Inc makes up approx 0.07% of Rs Investment Management Co’s portfolio. Blackrock Group Ltd added NK to its portfolio by purchasing 3,100 company shares during the most recent quarter which is valued at $20,677.Proshare Advisors reduced its stake in NK by selling 5,356 shares or 8.08% in the most recent quarter. The Hedge Fund company now holds 60,926 shares of NK which is valued at $487,408. Nantkwest Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Schwab Charles Investment Management Inc boosted its stake in NK in the latest quarter, The investment management firm added 459 additional shares and now holds a total of 19,875 shares of Nantkwest Inc which is valued at $159,000.Nationwide Fund Advisors boosted its stake in NK in the latest quarter, The investment management firm added 834 additional shares and now holds a total of 4,854 shares of Nantkwest Inc which is valued at $38,832.

Nantkwest Inc opened for trading at $6.74 and hit $6.9195 on the upside on Monday, eventually ending the session at $6.79, with a gain of 1.80% or 0.12 points. The heightened volatility saw the trading volume jump to 3,95,253 shares. Company has a market cap of $556 M.

On the company’s financial health, Nantkwest Inc reported $-0.55 EPS for the quarter, missing the analyst consensus estimate by $ -0.43 based on the information available during the earnings call on Nov 12, 2015. Analyst had a consensus of $-0.12. The company had revenue of $.01 million for the quarter, compared to analysts expectations of $.10 million. The company’s revenue was down -92.3 % compared to the same quarter last year.

Many Wall Street Analysts have commented on Nantkwest Inc. Shares were Reiterated by Canaccord Genuity on Apr 4, 2016 to “Buy” and Lowered the Price Target to $ 18 from a previous price target of $20 .Shares were Reiterated by FBR Capital on Mar 31, 2016 to “Outperform” and Lowered the Price Target to $ 29 from a previous price target of $30 .

NantKwest Inc. formerly Conkwest Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer infectious diseases and inflammatory diseases. The Company’s product candidates include aNK haNK and taNK. The Company’s aNK product candidates are unmodified aNK cells with natural affinity to stress-induced ligands of diseased cells. The Company develops its aNK product candidates as monotherapies for the treatment of virally-induced cancers such as polyomavirus induced Merkel cell carcinoma human Papillomavirus (HPV) induced cervical cancer and head and neck cancer. Its haNK product candidates are aNK cells genetically engineered to express high-affinity CD16 a receptor that allows direct binding of NK cells to antibodies. The Company’s taNK product candidate targets specific antigens on the surface of abnormal cells including CD33 EGFR HER2/neu PDL1 and PSMA.

Leave a Reply

Nantkwest Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nantkwest Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.